

Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C273320914E9EN.html>

Date: May 2024

Pages: 136

Price: US\$ 6,499.00 (Single User License)

ID: C273320914E9EN

Abstracts

The 7 major Clostridium difficile infection markets reached a value of US\$ 9.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 14.9 Billion by 2034, exhibiting a growth rate (CAGR) of 4.7% during 2024-2034.

The Clostridium difficile infection market has been comprehensively analyzed in IMARC's new report titled "Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Clostridium difficile infection (CDI) refers to a bacterial infection caused by the pathogenic bacterium Clostridium difficile, commonly known as C. difficile. This bacterium can colonize the colon and disrupt the normal balance of gut flora, leading to a range of gastrointestinal symptoms. The indications of CDI can vary in severity and may include watery diarrhea, abdominal pain, fever, loss of appetite, and nausea. In severe cases, the ailment can progress to pseudomembranous colitis, a more severe inflammation of the colon, which can result in life-threatening complications. Diagnosing CDI typically involves several steps. The primary method is to test a stool sample for the presence of C. difficile toxins or the bacterium itself. A positive test result, along with clinical symptoms, is often sufficient to confirm the infection. Additionally, healthcare providers may perform a colonoscopy or sigmoidoscopy to visually inspect the colon for signs of inflammation or pseudomembranes.

The increasing utilization of broad-spectrum antibiotics, which can impair the balance of beneficial bacteria in the colon, thereby allowing C. difficile to overgrow and produce toxins that cause infection, is primarily driving the Clostridium difficile infection market. In addition to this, the inflating demand for effective medications, including vancomycin and fidaxomicin, as well as the emerging use of fecal microbiota transplantation (FMT)

to restore a healthy gut microbiome, is also creating a positive outlook for the market. Moreover, the widespread adoption of infection control measures and stringent hygiene protocols in healthcare facilities, as they play a vital role in preventing CDI transmission, is further bolstering the market growth. Apart from this, the rising application of rapid diagnostic tests, such as enzyme immunoassays (EIAs) and nucleic acid amplification tests (NAATs), for early and accurate detection of the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative treatment modalities like monoclonal antibodies targeting bacterial toxins, which aid in neutralizing the harmful effects of the bacterium, is also augmenting the market growth. Furthermore, the ongoing research into novel vaccines against *C. difficile*, aimed at preventing CDI occurrence in high-risk populations is expected to drive the Clostridium difficile infection market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Clostridium difficile infection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Clostridium difficile infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Clostridium difficile infection market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the Clostridium difficile infection market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Clostridium difficile infection market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Clostridium difficile infection marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the Clostridium difficile infection market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Clostridium difficile infection market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Clostridium difficile infection market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Clostridium difficile infection across the seven major markets?

What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by type across the seven major markets?

How many patients are diagnosed (2018-2034) with Clostridium difficile infection across the seven major markets?

What is the size of the Clostridium difficile infection patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Clostridium difficile infection?

What will be the growth rate of patients across the seven major markets?

Clostridium Difficile Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Clostridium difficile infection drugs across

the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Clostridium difficile infection market?

What are the key regulatory events related to the Clostridium difficile infection market?

What is the structure of clinical trial landscape by status related to the Clostridium difficile infection market?

What is the structure of clinical trial landscape by phase related to the Clostridium difficile infection market?

What is the structure of clinical trial landscape by route of administration related to the Clostridium difficile infection market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 CLOSTRIDIUM DIFFICILE INFECTION - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 CLOSTRIDIUM DIFFICILE INFECTION - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 CLOSTRIDIUM DIFFICILE INFECTION - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (??2018-2034)
 - 7.2.4 Epidemiology by Gender (??2018-2034)
 - 7.2.5 Epidemiology by Type (??2018-2034)
 - 7.2.6 Diagnosed Cases (??2018-2034)
 - 7.2.7 Patient Pool/Treated Cases (??2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (??2018-2034)
 - 7.3.4 Epidemiology by Gender (??2018-2034)
 - 7.3.5 Epidemiology by Type (??2018-2034)
 - 7.3.6 Diagnosed Cases (??2018-2034)
 - 7.3.7 Patient Pool/Treated Cases (??2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (??2018-2034)
 - 7.4.4 Epidemiology by Gender (??2018-2034)
 - 7.4.5 Epidemiology by Type (??2018-2034)
 - 7.4.6 Diagnosed Cases (??2018-2034)
 - 7.4.7 Patient Pool/Treated Cases (??2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (??2018-2034)
 - 7.5.4 Epidemiology by Gender (??2018-2034)
 - 7.5.5 Epidemiology by Type (??2018-2034)
 - 7.5.6 Diagnosed Cases (??2018-2034)
 - 7.5.7 Patient Pool/Treated Cases (??2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (??2018-2034)
 - 7.6.4 Epidemiology by Gender (??2018-2034)
 - 7.6.5 Epidemiology by Type (??2018-2034)

- 7.6.6 Diagnosed Cases (??2018-2034)
- 7.6.7 Patient Pool/Treated Cases (??2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (??2018-2034)
 - 7.7.4 Epidemiology by Gender (??2018-2034)
 - 7.7.5 Epidemiology by Type (??2018-2034)
 - 7.7.6 Diagnosed Cases (??2018-2034)
 - 7.7.7 Patient Pool/Treated Cases (??2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (??2018-2034)
 - 7.8.4 Epidemiology by Gender (??2018-2034)
 - 7.8.5 Epidemiology by Type (??2018-2034)
 - 7.8.6 Diagnosed Cases (??2018-2034)
 - 7.8.7 Patient Pool/Treated Cases (??2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (??2018-2034)
 - 7.9.4 Epidemiology by Gender (??2018-2034)
 - 7.9.5 Epidemiology by Type (??2018-2034)
 - 7.9.6 Diagnosed Cases (??2018-2034)
 - 7.9.7 Patient Pool/Treated Cases (??2018-2034)

8 CLOSTRIDIUM DIFFICILE INFECTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 CLOSTRIDIUM DIFFICILE INFECTION - UNMET NEEDS

10 CLOSTRIDIUM DIFFICILE INFECTION - KEY ENDPOINTS OF TREATMENT

11 CLOSTRIDIUM DIFFICILE INFECTION - MARKETED PRODUCTS

11.1 List of Clostridium Difficile Infection Marketed Drugs Across the Top 7 Markets

11.1.1 Zinplava (Bezlotoxumab) - Merck & Co

11.1.1.1 Drug Overview

11.1.1.2 Mechanism of Action

11.1.1.3 Regulatory Status

11.1.1.4 Clinical Trial Results

11.1.1.5 Sales Across Major Markets

11.1.2 Rebyota (fecal microbiota, live - jsIm) - Rebiotix

11.1.2.1 Drug Overview

11.1.2.2 Mechanism of Action

11.1.2.3 Regulatory Status

11.1.2.4 Clinical Trial Results

11.1.2.5 Sales Across Major Markets

11.1.3 Vowst (fecal microbiota spores, live-brpk) - Seres Health

11.1.3.1 Drug Overview

11.1.3.2 Mechanism of Action

11.1.3.3 Regulatory Status

11.1.3.4 Clinical Trial Results

11.1.3.5 Sales Across Major Markets

11.1.4 Difucid (Fidaxomicin) - Merck

11.1.4.1 Drug Overview

11.1.4.2 Mechanism of Action

11.1.4.3 Regulatory Status

11.1.4.4 Clinical Trial Results

11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 CLOSTRIDIUM DIFFICILE INFECTION - PIPELINE DRUGS

12.1 List of Clostridium Difficile Infection Pipeline Drugs Across the Top 7 Markets

12.1.1 VE303 - Vedanta Biosciences

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 RBX7455 - Rebiotix

12.1.2.1 Drug Overview

- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status
- 12.1.3 CP101 - Finch Research and Development
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 MGB BP 3 - MGB Biopharma
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 PF-06425090 - Pfizer
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report

13. CLOSTRIDIUM DIFFICILE INFECTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. CLOSTRIDIUM DIFFICILE INFECTION – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 CLOSTRIDIUM DIFFICILE INFECTION - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets

- 15.2.1 Clostridium Difficile Infection - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Clostridium Difficile Infection - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Clostridium Difficile Infection - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Clostridium Difficile Infection - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Clostridium Difficile Infection - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Clostridium Difficile Infection - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Clostridium Difficile Infection - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Clostridium Difficile Infection - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Clostridium Difficile Infection - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Clostridium Difficile Infection - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Clostridium Difficile Infection - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Clostridium Difficile Infection - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Clostridium Difficile Infection - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Clostridium Difficile Infection - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy

- 15.7.1 Clostridium Difficile Infection - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Clostridium Difficile Infection - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Clostridium Difficile Infection - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Clostridium Difficile Infection - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Clostridium Difficile Infection - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Clostridium Difficile Infection - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Clostridium Difficile Infection - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Clostridium Difficile Infection - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Clostridium Difficile Infection - Access and Reimbursement Overview

16 CLOSTRIDIUM DIFFICILE INFECTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 CLOSTRIDIUM DIFFICILE INFECTION MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 CLOSTRIDIUM DIFFICILE INFECTION MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C273320914E9EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C273320914E9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

